Tag: PAD

European launch: Medtronic receives CE mark for 200mm and 250mm IN.PACT...

Medtronic has announced the European launch of the 200mm and 250mm IN.PACT Admiral drug-coated balloons (DCBs) following CE mark approval. The product is intended to treat long...

PAD: R3 Vascular reports ‘successful initiation’ of first-in-human study of bioresorbable...

Medical device developer R3 Vascular has reported the "successful initiation" of a first-in-human clinical study evaluating the technical and clinical performance of its Magnitude...

Physicians draw attention to Medicare cuts as PAD Awareness Month kicks...

A coalition of physicians and other interested parties focused on peripheral arterial disease (PAD) has called on Congress and the Centers for Medicare and...

Females were 30% less likely to undergo surgery for PAD, national...

A review of more than 1 million patients receiving vascular surgery over a 16-year period identified significant sex-related disparities in the treatment of abdominal...

USPSTF expands screening recommendation for prediabetes, type-2 diabetes to adults aged...

The United States Preventive Services Task Force (USPSTF) has issued an updated recommendation statement suggesting clinicians screen for prediabetes and type-2 diabetes in overweight...

VAM discussion on latest paclitaxel meta-analysis yields mix of caution, skepticism

A Vascular Annual Meeting (VAM) sponsored session on paclitaxel safety drew a mix of skeptical and cautious responses to the latest meta-analysis from interventional...
x-ray image below knee amputation or BKA amputation

Amputation rates higher for people with PAD who are poor or...

Poverty and Black race were associated with higher rates of lower-leg amputation among people with peripheral arterial disease (PAD) who live in metropolitan areas, according to new...

Vascular Quality Initiative launches ‘My PAD’ pilot

The Society for Vascular Surgery (SVS) Vascular Quality Initiative (VQI) has created “My PAD,” a pilot program for collecting patient-reported outcomes (PROs) from patients...

FDA approves expanded PAD indication for rivaroxaban plus aspirin

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Food and Drug Administration (FDA) has approved an expanded peripheral arterial disease...

Veterans with claudication who undergo revascularization ‘significantly more likely to have...

Patients within the Veterans Affairs Administration healthcare system who underwent an intervention for intermittent claudication (IC) were consistently at three-to-four times greater risk of...

‘Let’s move on to solutions,’ keynote speaker tells diversity, equity and...

Lee Kirksey, MD, issued an unapologetic apology of sorts at the outset of his discussion of diversity, equity and inclusion (DEI) issues. “If I...

Colombian researchers report positive 24-month results for VenoValve

Promising two-year results for an emerging potential prosthetic venous valve replacement—which is about to commence a U.S. pivotal trial—were announced at the Vascular Annual...

Research letter highlights low adoption of supervised exercise therapy for PAD

A research letter published in Circulation: Cardiovascular Quality and Outcomes highlights a “very low” utilization of supervised exercise therapy (SET) in symptomatic peripheral arterial disease (PAD) patients...

VOYAGER PAD: Rivaroxaban plus aspirin should be considered after lower-extremity bypass...

“A strategy of adding rivaroxaban 2.5mg twice daily to aspirin should be considered after lower extremity bypass regardless of conduit type,” concluded Nicholas Govsyeyev,...

PRISTINE registry with Selution SLR sirolimus drug-eluting balloon completes enrollment

MedAlliance has announced completion of patient enrollment in the PRISTINE clinical trial with the Selution SLR 018 drug-eluting balloon (DEB) for the treatment of patients with below-the-knee...

VAM: Industry-sponsored symposia

Industry-sponsored symposia at the Vascular Annual Meeting (VAM) will be presented Wednesday and Thursday evenings and at three breakfast sessions taking place Thursday morning....

Study of amputees finds referral for prosthetics to be an independent...

Prosthetic referral was an independent predictor of long-term survival among patients who had undergone lower-extremity amputation, new findings set to be published in the...

AHA publishes updated scientific statement on PAD

The American Heart Association (AHA) has released a new scientific statement on lower extremity peripheral arterial disease (PAD), focusing on contemporary epidemiology, management gaps, and future directions. The...

Special session on diversity enters VAM agenda

Over the course of more than a year, diversity, equity and inclusion (DEI) have been brought into sharp focus by a compendium of events...

The year in COVID: VAM to feature 10 talks probing pandemic-related...

After nearly 18 months of life dominated by a worldwide pandemic—one that canceled the 2020 Vascular Annual Meeting (VAM)—VAM 2021 highlights several aspects of...

Introducing patient-reported outcomes into the VQI

Vascular specialists have long recognized that there is more to the treatment of peripheral arterial disease (PAD) than the immediate procedural success and early...

Fighting the good fight: The case for multidisciplinary limb salvage in...

Dramatic increases in rates of diabetes—particularly among Black females—through 2060 underscore the importance of a multidisciplinary team approach to limb salvage, according to Vincent...

Fempop bypass shows reintervention benefit over endovascular therapy for advanced premature...

Femoropopliteal bypass is associated with decreased reinterventions at one year compared to endovascular therapy in patients with advanced premature peripheral arterial disease (PAD). This is...

The top 10 most popular Vascular Specialist stories in May

A pointed letter aimed at electronic health record (EHR) behemoth Epic, an argument in favor of endovascular treatment of ruptured abdominal aortic aneurysms (rAAAs)...

Pearls of wisdom for interns

It’s June and, in less than a month, a swarm of new faces, and freshly minted MDs and DOs will descend upon most academic...

Philips announces positive two-year data from TOBA II BTK clinical trial

Royal Philips recently announced positive two-year results from the TOBA (Tack optimized balloon angioplasty) II below-the-knee (BTK) clinical trial. The data show the Philips Tack endovascular...

Stenting found to be superior to atherectomy, balloon angioplasty in reducing...

Stenting reduced mortality risk in patients undergoing interventions for peripheral arterial disease (PAD) by more than 30% when compared to plain balloon angioplasty, and...

One-year results from PROMISE I study of LimFlow system in ‘no-option’...

Twelve-month data from the full patient cohort in the PROMISE I study of the LimFlow percutaneous deep vein arterialization (pDVA) system have been...

ACC.21: SAFE-PAD finds no increased risk of death with drug-coated devices

Researchers have found no statistically significant difference in mortality between patients treated with drug-coated devices and non-drug-coated devices in the SAFE-PAD study. Eric Secemsky,...

ACC.21: VOYAGER PAD shows rivaroxaban ‘significantly’ reduced total ischemic events in...

Rivaroxaban combined with low-dose aspirin led to a significant reduction in the occurrence of total ischemic events in patients with symptomatic peripheral arterial disease...

Intermittent claudication and exercise therapy: A poor SET-up

Many of you may have already heard about the controversial Comparative Billing Reports (CBRs) that have been received by some of our vascular surgery...

The top 10 most popular stories from April

Our April cover story on the links between electronic health records (EHRs) and physician burnout, the continuing problem of manels (or all-male speaking panels)...

MicroStent to treat PAD below the knee receives FDA breakthrough device...

Micro Medical Solutions (MMS) recently revealed Food and Drug Administration (FDA) breakthrough device designation for its MicroStent vascular stent. This novel technology is designed...

Interventions associated with ‘poor’ two-year relief of intermittent claudication symptoms

Peripheral vascular interventions for intermittent claudication were linked to "poor" two-year relief of symptoms in the Vascular Quality Initiative (VQI) database, a new study...

SoundBite peripheral crossing system gains FDA approval

Soundbite Medical Solutions has announced Food and Drug Administration (FDA) 510(k) approval for the SoundBite crossing system—Peripheral (SCS-P) with the 0.014” active wire (14P). The...

PAD: Endologix acquires PQ Bypass

Endologix recently announced completing the acquisition of PQ Bypass, a medical technology company pioneering a first-of-its-kind technology that addresses severe peripheral arterial disease (PAD). PQ...

Lessons in PAD care from VA vascular surgeons

The care of patients with peripheral arterial disease (PAD) is challenging and costly. Every practicing vascular surgeon knows that when patients present with ulcerations,...

Surmodics announces first patient uses of two Sublime radial access platform...

Surmodics recently announced the successful first uses in patients for two devices within its Sublime radial access platform: the Sublime radial access guide sheath and...

Study identifies ‘critical need’ for guidelines on appropriate use of atherectomy

No data currently exist to support the use of atherectomy over other procedures for the treatment of peripheral arterial disease (PAD), and the healthcare...

SVS SET: PAD patient walks away from pain

Ice, cold and snow make it tough to walk outside in Lansing, Michigan, right now. So, jokes Doug Giller, he is wearing a path...

Coaches ‘integral’ to SVS SET app program

“A good coach will make his players see what they can be rather than what they are.” Those are words ascribed to football coach...

Supervised Exercise Therapy: There’s an app for that

Call it timing on several fronts, each part coming together for the benefit of patients with peripheral arterial disease (PAD). Included in the mix was...

Postmarket study of sirolimus-eluting balloon enrolls first patient

MedAlliance has announced enrollment of the first patient in SUCCESS PTA, its large post-market study with the drug-eluting balloon Selution SLR for the treatment...

Veterans study: No evidence of increased risk of death with use...

A study of more than 10,000 U.S. veterans with peripheral arterial disease (PAD) undergoing endovascular interventions in the femoropopliteal segment found that rates of...

How to succeed in vascular surgery: A guide for the aspiring...

Disclaimer: The views expressed here do not reflect those of Mayo Clinic, the Society for Vascular Surgery, Vascular Specialist, or even the author, for...

Walking can relieve leg pain in people with PAD

Exercise can play an important role in treating peripheral arterial disease (PAD), a recent review by Amy Harwood, PhD, from the Centre for Sport and...

Target 2021: SVS councils and committees drill down on key goals...

While there is little doubt the pandemic has impacted each vascular surgeon and the SVS as a Society in numerous ways, the commitment and...

‘Successful’ first-in-human use of the Efemoral scaffold system announced

Efemoral Medical has announced the first-in-human (FIH) use of the company’s Efemoral Vascular scaffold system (EVSS) with FlexStepv technology in the EFEMORAL I FIH...

WIfI score found to be accurate across racial groups

The wound, ischemia and foot infection (WIfI) score is as accurate a predictor of risk for limb loss in Black people as it is...

Revascularization ‘improves’ walking performance in claudicating PAD patients 

Revascularization of the lower extremity improves hemodynamics, walking performance, quality of life and calf-muscle pathology in claudicating patients with peripheral arterial disease (PAD), researchers...

VOYAGER PAD: Rivaroxaban plus aspirin versus aspirin alone among CLTI patients...

In one of the latest sub-analyses from the VOYAGER PAD trial, investigators found that rivaroxaban plus aspirin versus aspirin alone in the high-risk population...

Previously described patient-centered clinical success measure after revascularization for diabetic foot...

Patient-centered clinical success after lower-extremity revascularization for people with diabetic foot wounds was achieved among 63% of patients in a new analysis—but researchers suggest...

Intravascular lithotripsy superior to PTA in acute procedural success out to...

The DISRUPT PAD III randomized controlled trial (RCT) provides the largest level-one evidence for the treatment of heavily calcified femoropopliteal arteries, noted William Gray,...

Latest VOYAGER PAD analysis finds no mortality and improved limb outcomes...

Given the absence of a safety signal in data from the VOYAGER PAD trial, a new analysis examined the potential benefit of drug-coated device...

Utilize new SVS Branding Toolkit

The new SVS Branding Toolkit—a robust set of tools designed to help members communicate their roles in comprehensive vascular care—is now available exclusively and...

Janssen applies to FDA for new indication to expand use of...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the Food and Drug...

New analysis finds DCBs lead to greater four-year survival after fempop...

Patients treated with a paclitaxel-coated balloon saw greater survival, freedom from amputation and amputation-free survival through four-year follow-up after their initial femoropopliteal revascularization operation...

Hodgson: Bringing appropriateness into sharper focus

In 2019, Kim Hodgson, MD, kicked off his presidential year by placing appropriateness and quality of care under the microscope. His turn organizing the...

Vascular Specialist–October 2020

In this issue: Special interview: Kim Hodgson, MD, discusses his SVS presidency, his appropriateness-in-care agenda, the new SVS SET app, and his post-presidential priorities...

VA system delivers high quality services for veterans

Vascular surgery in the Veterans Health Administration has always been a robust service, developing into a mature specialty around the time of the Vietnam...

‘No signal of increased risk of long-term mortality’ with paclitaxel-coated Luminor...

An ad hoc, two-year analysis of the EffPac study found no signal of increased risk of long-term mortality, nor any adverse events, within two years...

Disproportionately more women are affected by depression when pursuing specialty PAD...

A disproportionately higher percentage of women are affected by depressive symptoms when they seek specialty care for new or worsening peripheral arterial disease (PAD)...

High level of heterogeneity found in randomized PAD trial antithrombotic regimens

A recent systematic review showed that randomized trials comparing different types of peripheral endovascular arterial intervention have a high level of heterogeneity in their...

Diversity, equity and inclusion: Disparities in medicine and vascular surgery

Recent months have yielded a conversation on systemic racism perhaps unlike any other before. We’ve learned about how it manifests across society, how it...

‘If I had gone along the path advised, I would never...

Some of the formative educational experiences described by Olamide Alabi, MD, read like textbook examples of the subtleties many see as baked into U.S....

Doubted as a doctor during mid-flight medical emergency and once asked:...

In a vascular surgery career spanning 20 years, Vincent Rowe, MD, has seen it all: Tending to patients at bedside, the vascular surgical services...

‘Casting a wider net’ when researching genetic and molecular factors of...

For vascular surgeon and research scientist Elsie Gyang Ross, MD, the world of data science might hold some of the answers to the kind...

‘Improving disparities in healthcare is not a matter of slapping some...

Andrew Gonzalez, MD, had a heart for underserved and under- resourced communities embedded early. The son of a pediatric hematologist mother who worked at...

Black patients in areas with lowest PAD rates disproportionally at higher...

It’s among the most topical areas of discussion in current U.S. cultural life: Black people face disparities in terms of healthcare outcomes. And the...

SVN to host virtual annual meeting July 15

The Society for Vascular Nursing (SVN) 38th Annual Conference—a virtual meeting—will be held from 6 to 9:30 p.m. Central Daylight Time Wednesday, July 15. In...

International Lecture: Endovascular colossus discusses new PAD therapy

A new therapy of hydration and oncotic pressure of plasma helped 100% of certain elderly peripheral artery disease (PAD) patients in terms of pain,...

SVS pilots SET app for peripheral artery disease patients

Doctor-prescribed and -supervised exercise therapy is going digital. The Society for Vascular Surgery (SVS) will begin piloting a ground-breaking app for Supervised Exercise Therapy...

SVS in transition: A look back, a look ahead

Each Society for Vascular Surgery (SVS) president wishes for a memorable annual meeting, outgoing SVS president Kim Hodgson, MD, noted during his State of...

TOBA III clinical trial results published

Intact Vascular has announced the peer-reviewed publication of its Tack optimized balloon angioplasty (TOBA) III 12-month clinical trial results in the Journal of Vascular Surgery. The multi-center, single-arm,...

Technology drives vascular future

Decades ago, “picture” phones were an idea straight out of science fiction. As the saying goes, the future is now. FaceTime and Skype are...

Quality: Global Vascular Guidelines pocket guide coming soon

The Global Vascular Guidelines (GVG), extensively researched and written by an international committee of leading vascular experts, will soon be available as a pocket...

Clopidogrel exposure along with aspirin and rivaroxaban should be ‘minimized or...

“More bleeding with background clopidogrel, even if not severe by adjudication, may be associated with broad consequences, including discontinuation of therapies. In the absence...

Combining aspirin with rivaroxaban reduces risk equally in presence or absence...

In stable atherosclerosis, a combination of aspirin plus rivaroxaban provided a similar relative degree of benefit on coronary, cerebrovascular and peripheral endpoints in patients...

Aspirin plus rivaroxaban significantly lowers adverse events in PAD revascularization

Treatment with aspirin plus rivaroxaban following lower-extremity revascularization in patients with peripheral arterial disease (PAD) leads to a 15% reduction in the risk of...